

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Shanghai Bio-heart Biological Technology Co., Ltd.**

### **上海百心安生物技術股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2185)**

## **UPDATE ON QUALIFICATION OF THE JOINT COMPANY SECRETARY**

Reference is made to the prospectus (the “**Prospectus**”) of Shanghai Bio-heart Biological Technology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) dated December 13, 2021 in relation to the waiver granted to the Company by The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) from strict compliance with Rules 3.28 and 8.17 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) in respect of the eligibility of Mr. Yunqing Wang (“**Mr. Wang**”) to act as one of the joint company secretaries of the Company (the “**Joint Company Secretary(ies)**”) for an initial three-year period commencing from December 23, 2021 (being the date of listing of the Company on the Stock Exchange) to December 22, 2024 (the “**Waiver Period**”).

The Company hereby announces that on January 21, 2025, the Stock Exchange has confirmed that, upon the expiry of the Waiver Period, Mr. Wang has acquired the relevant experience within the meaning of Note 2 to Rule 3.28 of the Listing Rules, and is capable of discharging the functions as the company secretary independently (the “**Qualification**”) and thus a further waiver is no longer necessary. With a view to pursue the higher standard of corporate governance, the Company will continue to retain the arrangement of Joint Company Secretaries under which Ms. Sarah Siu Ying Kwok (“**Ms. Kwok**”), the current Joint Company Secretary, will continue to assist Mr. Wang in performing his duties.

As the Company was in the process of preparing certain information to be included in the circular relating to a major transaction in relation to the deemed disposal of equity interest in a subsidiary of the Company and Mr. Wang fully engaged in the whole process, and therefore additional time was required to, among other things, prepare the letter to the Stock Exchange to demonstrate the Qualification of Mr. Wang upon expiry of the Waiver Period and address the requirements under the Listing Rules, there was an inadvertent delay (the “**Delay**”) in seeking confirmation from the Stock Exchange regarding the eligibility of Mr. Wang to act as the Company Secretary pursuant to Rule 3.28 of the Listing Rules, during which time Mr. Wang continued to be assisted by Ms. Kwok. From the expiry of the Waiver Period to January 20, 2025, Mr. Wang’s Qualification had not been confirmed or waived by the Stock Exchange. However, the Company believes the Delay has no bearing on Mr. Wang’s Qualification as (i) Mr. Wang has been working closely and received full support from Ms. Kwok and the legal adviser of the Company during the Delay; and (ii) Mr. Wang has extensive experience and continuous training and is familiar with the rules and requirements of the Listing Rules and other relevant laws and regulations.

By Order of the board of  
**Shanghai Bio-heart Biological Technology Co., Ltd.**  
**Philip Li WANG**  
*Chairman and executive director*

Shanghai, the People’s Republic of China, January 23, 2025

*As at the date of this announcement, the board of directors of the Company comprises Mr. Philip Li WANG as Chairman and executive director, Mr. Yunqing WANG and Ms. Peili WANG as executive directors, and Mr. Yiqing CHEN, Mr. Xubo LU and Mr. Yifei JIANG as independent non-executive directors.*